How To Address The ‘Shocking Tale Of Neglect’ In Aged Care Through Transparency, Accountability, And The Use Of High-Quality Analytics
Funder
National Health and Medical Research Council
Funding Amount
$1,337,350.00
Summary
The Royal Commission into Aged Care shows that an improved understanding of how the aged care sector is caring for older Australians is a national priority. The Registry of Senior Australians, a large-scale registry database that I developed, will be used to evaluate the health and wellbeing of older Australians. This research will enable me to develop and implement a transparent outcome monitoring system and tools to address the “Shocking Tale of Neglect” older Australians are experiencing.
We aim to discover and develop a blood test that can predict which lung cancers have spread to lymph glands in the chest, to help decide on the best treatment options.
Role Of FLT PET In Malignant Pleural Mesothelioma - Prediction Of Response To Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$93,639.00
Summary
Mesothelioma is a cancer of the lining of the lung. Chemotherapy is often used to treat patients in order to reduce their symptoms and to improve quality and length of life. Not all patients however benefit from chemotherapy, and most patients will experience some side-effects. Currently CT scans are used to assess response to chemotherapy, however the way that mesothelioma grows makes measuring response difficult. CT scans also are not very sensitive in detecting response early - often 3 or 4 c ....Mesothelioma is a cancer of the lining of the lung. Chemotherapy is often used to treat patients in order to reduce their symptoms and to improve quality and length of life. Not all patients however benefit from chemotherapy, and most patients will experience some side-effects. Currently CT scans are used to assess response to chemotherapy, however the way that mesothelioma grows makes measuring response difficult. CT scans also are not very sensitive in detecting response early - often 3 or 4 cycles of treatment (3-4 months) are required before benefit is seen. A test that could predict which patients were benefiting after only 1 cycle (3-4 weeks) of chemotherapy would be a great advantage, and may spare some patients unnecessary and potentially toxic treatment. Fluorothymidine (FLT) is a radioactive tracer that, after injection into a vein, is taken up by dividing cells. Tumour cells usually divide more actively than surrounding normal cells, and therefore when a positron emission tomography (PET) scan is performed it will demonstrate the tumour as a 'hot spot'. The amount of FLT uptake into the tumour depends on how much DNA synthesis (active cell division) is occurring. After chemotherapy, if the tumour responds it would be expected that the amount of FLT in the tumour will reduce. This can be assessed by repeating the FLT PET scan after the first cycle of chemotherapy. This study aims to assess the ability of the change in FLT uptake in mesothelioma after 1 cycle of chemotherapy to predict response, as measured on CT scans, and patient outcomes such as quality of life and survival. It is hoped that if successful this type of scan may improve patient care by selecting those who are likely to benefit from chemotherapy early and avoid unnecessary toxicity to patients who will not benefit from the treatment.Read moreRead less
In Australia, over 2000 families suffer the tragedy of stillbirth each year. By building on our achievements of the first Stillbirth CRE rapidly translating new research into maternity care, we will reduce stillbirth rates by 20%, and reduce inequities in stillbirth rates by Australia by 2025. We also anticipate a reduction in adverse neonatal outcomes. When stillbirth or neonatal death does occur, our research aims to ensure that all women and families receive optimal care.
Staying Connected: Personalising Stroke Recovery And Rehabilitation Through New Technologies For People With Stroke Living At Home.
Funder
National Health and Medical Research Council
Funding Amount
$1,730,999.00
Summary
One in 4 people experience a stroke. On return home the person with stroke is challenged to sense, move, think, and engage in valued activities with an altered brain and body. Yet the current approach to ongoing recovery is limited. We propose to: monitor for markers of recovery using personalised sensors and artificial intelligence; deliver bursts of therapy at point of need, at home; and provide feedback through new technologies and a central hub...to stay connected, and to recover at home.
Prediction Of Fracture By Clinico-genetic Profiling
Funder
National Health and Medical Research Council
Funding Amount
$2,339,215.00
Summary
The loss of bone with advancing age is the main cause of osteoporosis and bone fracture. Bone loss is highly variable between individuals, and we are not sure why. I want to find out factors that contribute to bone loss, and then use this knowledge to identify individuals at high risk of excessive bone loss for early prevention. My goal over the next 5 years is to create a new clinico-genetic model for assessing the rate of bone loss, and predicting the risk of fracture for an individual.
Gastric Cancer: Early Detection Of Disease, Relapse And Prediction Of Extent Of Disease
Funder
National Health and Medical Research Council
Funding Amount
$421,800.00
Summary
Gastric cancer (GC) is the second commonest cause of cancer in the world. The mainstay of treatment for GC is surgical resection, but despite improvements in surgical interventions the mortality rate remains high. The 5 year survival rate of GC is about 30% over 5 years. Accurate staging is fundamental to the management of GC and current investigations are inadequate. It has become possible to measure the activity of thousands of genes to identify those genes that predict whether a patient will ....Gastric cancer (GC) is the second commonest cause of cancer in the world. The mainstay of treatment for GC is surgical resection, but despite improvements in surgical interventions the mortality rate remains high. The 5 year survival rate of GC is about 30% over 5 years. Accurate staging is fundamental to the management of GC and current investigations are inadequate. It has become possible to measure the activity of thousands of genes to identify those genes that predict whether a patient will survive or succumb to their disease. We propose to use gene expression profiling to predict the risk of recurrence of gastric cancer in patients. We will examine over 270 tumours and use an independent group of patients to evaluate the test. We aim to develop a test that will help the clinician decide the type of surgical resection to perform or whether to give adjuvant chemotherapy. The test may also guide the use of more specific anticancer drugs. Early detection of GC is very important because patients with early stage GC have better outcome. We have already analysed over 60 GC tumours with microarrays and found genes that are specifically expressed by the tumours that are potential candidates as cancer markers. We plan to examine more cases of GC, both to find more genes and validate our candidate genes as tumour markers. We also want to look for patterns of proteins in blood of patients that identifies GC and use this pattern to follow patient progress to treatment.Read moreRead less
The Landscape Of Cancer Genes And Associations With Prognosis In Breast Cancer Diagnosed In Premenopausal Women
Funder
National Health and Medical Research Council
Funding Amount
$700,512.00
Summary
Using state of the art technology, the purpose of this project is understand the implications of known cancer mutations in breast cancer diagnosed in premenopausal ER-positive breast cancer. Mutations are abnormalities in the DNA of genes that can provide a signal for uncontrolled growth, a hallmark of cancer. The unique aspect of this project is use of tissue samples from patients who were diagnosed with breast cancer at a young age. This information will help us develop new treatments.